
Rio: Where joy rises, and the hills rejoice
High above Rio, Christ the Redeemer 'watches' in silence.
RIO de Janeiro is a city where joy is not merely found in its people, colours or its music, but it arises from the land itself.
From the sunrise over Guanabara Bay, the seabirds soaring over the Atlantic and the stretched wide arms of Christ the Redeemer atop Corcovado Mountains – there is beauty and joy unlimited.
After writing about the colours of Rio – the bohemian flair of Santa Teresa, the vibrant steps of Selarón, and the carnival of sights and sounds at the Hippie Market – I turned my gaze upward and outward.
The nature of Rio calls just as loudly and boldly as its culture and people.
Its mountains and seas offer a different kind of beauty, one that is steady, grounding, and quietly transcendent.
And as I stood before these wonders, the words of an old hymn came to mind: 'You shall go out with joy, and be led forth with peace; the mountains and the hills will break forth before you… and all the trees of the field shall clap their hands.'
High above Rio, on the 710-metre Corcovado peak, stands the Christ the Redeemer statue, 'Cristo Redentor'.
I have seen countless photos of this wonder and read about its symbolism and stature before I came, but nothing prepares me for seeing it in person.
The journey up began at 7.20am through the Tijuca Forest, where a lush green corridor came alive with birdsong and mist.
As the narrow road brought me upward, excitement and anticipation built up with every turn.
Reaching the summit, the statue emerged – not just as a monument of reinforced concrete and soapstone, but it is a presence.
The wide open arms was a gesture that did not domineer, but one that was embracing, forgiving, sheltering and most of all, unafraid.
There and then, I felt the gentleness of that open and welcoming arms – perhaps that was one of the reasons Christ the Redeemer was named one of the 'New Seven Wonders of the World'.
It is not just the sheer size – 30 metres high, with arms stretching 28 metres wide – but the way it commands the landscape.
The magnificent stature does not give a feeling that it is looking down in judgement, but, for a while, I feel it is gazing over the city with quiet compassion.
My tour guide, in his wisdom, suggested that we start early so that there would not be many tourists and that I could feel and think the message 'Christ the Redeemer' bringing in its personal way to me.
I found myself simply still. There was surely something about the wind up there and the proximity to the sky, which made the noise inside fall silent.
Perhaps it was peace, or awe – or both.
In the distance, the hills did seem to break forth. The song felt real.
From one marvel to another: Sugarloaf Mountain, or 'Pão de Açúcar', stands as a watchful monument at the entrance of Guanabara Bay.
If Christ the Redeemer is Rio's spiritual crown, then the Sugarloaf is its 'lighthouse' – watching over the coast.
Bernard said the Portuguese colonisers named the mountain 'Sugarloaf' because its granite peak resembled the conical sugar moulds used for sugar refinement during the 16th century.
The summit of Sugarloaf Mountain provides a complete view of Rio de Janeiro.
The cable car ride up Sugarloaf is in itself an adventure.
Suspended in a glass capsule, standing inside, you feel that you are floating between the sea and the sky with the city below shrinking into a mosaic of red roofs, green parks, and sapphire water.
The city exists between mountain ranges and ocean-fronts as a natural masterpiece that connects through its grand landscapes.
The air at this height carries a distinct salty flavour while birds glide effortlessly through the sky as if happiness had a physical form.
According to Bernard, many tourists are making a trip up to Sugarloaf for the sunset view.
He described that as the sun began to set, the entire landscape turned gold. The bay shimmered like liquid brass.
Even though it was not a sunset when I visited, the line from Isaiah returned: 'All the trees of the field shall clap their hands.'
It is not hard to believe that creation itself is celebrating.
There's something poetic, even divine, about Rio de Janeiro's topography.
It is a city defined by extremes – high peaks and low bays, sacred silence and samba rhythms, solitude and celebration.
These contrasts do not compete, but they complement.
The mountains remind us to look up. The seas remind us to let go.
Together, they offer a geography of grace.
It's easy to be overwhelmed by Rio's man-made marvels – its music, its food, its football – but nature always has the last word.
The mountains and seas were here long before colonists arrived, or concrete was poured – and they will remain long after we're gone.
For me, Rio wasn't just a city to tick off a travel list.
It became a place of personal reflection.
As someone used to the quiet hills of Borneo, I felt an unexpected kinship with Rio's rugged terrain. It felt familiar yet foreign, distant, yet deeply intimate.
Christ the Redeemer and Sugarloaf may be landmarks, but they are also metaphors – for hope, for faith, for resilience.
I left Rio with many photographs, but the image that stayed in my heart was not a perfect sunset or a bustling street.
It was the silhouette of the Christ statue, arms open to the wind, framed by clouds that seemed to clap in joy.
In a world that moves at fast pace and stressful, Rio's mountains and seas offer a kind of healing.
Not the loud kind, but the quiet and enduring kind.
So yes, I did go out with joy. I was led forth in peace. The mountains broke forth before me – not in grand explosions, but in quiet reminders of wonder.
And the trees?
I swear I heard them clap. brazil Christ the Redeemer Corcovado Mountains Guanabara Bay Rio de Janeiro

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a few seconds ago
- Globe and Mail
Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Vitiligo Pipeline Insight, 2025 ' report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report Key Takeaways from the Vitiligo Pipeline Report In August 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo. In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone. DelveInsight's Vitiligo pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Vitiligo treatment. The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies Vitiligo Emerging Drugs Profile Afamelanotide: Clinuvel, Inc. Afamelanotide, developed by Clinuvel, Inc., is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) designed to promote skin pigmentation in individuals with vitiligo. It works by activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating melanin production and distribution in depigmented areas of the skin. Afamelanotide is administered via a subcutaneous implant, offering a systemic approach that may enhance repigmentation, particularly when used in combination with controlled UV light therapy. Its mechanism addresses the underlying pigment loss in vitiligo, aiming to restore skin tone more uniformly and effectively. Currently, the drug is in Phase III stage of its development for the treatment of Vitiligo. VYN201: Vyne Therapeutics Inc. Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a 'soft' drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. BET proteins play a key role in regulating gene transcription via epigenetic interactions ('reading'). Recent research has identified a key role for these proteins in regulating activation of immune cells, including T cells and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with additional potential in myeloproliferative neoplastic disorders. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration). Currently, the drug is in Phase II stage of its development for the treatment of Vitiligo. FB102: Forte Biosciences, Inc. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company's FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Vitiligo. The Vitiligo Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment. Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market. Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs Vitiligo Companies Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Vitiligo Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives Scope of the Vitiligo Pipeline Report Coverage- Global Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo Pipeline Therapies- Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report—access it now! @ Vitiligo Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Vitiligo: Overview Pipeline Therapeutics Therapeutic Assessment Vitiligo– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Afamelanotide: Clinuvel, Inc. Mid Stage Products (Phase II) VYN201: Vyne Therapeutics Inc. Early Stage Products (Phase I) FB102: Forte Biosciences, Inc. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Vitiligo Key Companies Vitiligo Key Products Vitiligo- Unmet Needs Vitiligo- Market Drivers and Barriers Vitiligo- Future Perspectives and Conclusion Vitiligo Analyst Views Vitiligo Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.


Globe and Mail
a few seconds ago
- Globe and Mail
Bullet Blockchain Announces Strategic Initiatives to Accelerate Growth and Cement Market Leadership
LAS VEGAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bullet Blockchain, Inc. (OTC: BULT) ('Bullet Blockchain' or the 'Company'), the only U.S. company holding foundational patents for Bitcoin ATMs and one of only three publicly traded Bitcoin ATM network owner/operators, today announced a series of key strategic initiatives that management is pursuing to drive an aggressive expansion and align current and future stakeholders with the Company's long-term vision. 'We have a clear strategy to capitalize on the explosive growth of the crypto ATM market,' said Simon Rubin, CEO of Bullet Blockchain. 'Our primary focus is on four core pillars: (i) Expanding our operational footprint; (ii) Strengthening our leadership and governance; (iii) Securing the strategic capital necessary to fuel this growth; and, (iv) Forging strategic alliances for enhanced security and utility. 'These initiatives are designed to build a powerful foundation for Bullet Blockchain's future and reinforce our position as an industry innovator.' The first of these pillars is focused on a multi-pronged approach to scaling the Company's physical presence and network capacity. Expanding Our Operational Footprint Bullet Blockchain is actively pursuing opportunities to dramatically accelerate the deployment of its Bitcoin ATM network (a/k/a/ 'crypto ATM network'). Building on a successful start, the company is now focused on a multi-pronged approach to scaling its operations. This includes exploring opportunities to acquire and deploy a significant number of new and refurbished crypto kiosks from both manufacturers and operators. In tandem with this effort, management is in active discussions with a number of regional and national retail operators, including convenience stores and gas station chains, to secure distribution agreements. Such agreements would support a more rapid and strategic rollout of the Company's network, with the potential to significantly expand Bullet's presence across the country. The Company is committed to upholding the highest standards of corporate governance, intellectual property protection, and market compliance. To support these imperatives, Bullet Blockchain is actively engaging with highly qualified individuals to enhance its executive team and Board of Directors. This includes seeking out specialists in intellectual property to advise on strategies for enforcing and leveraging the company's foundational patents, as well as interviewing qualified candidates to join the Board. Further, management is actively seeking to engage new auditing firms with the intent of fast-tracking important compliance initiatives, signaling a clear path towards increased transparency and market status. To execute its aggressive growth plan, Bullet Blockchain is strategically pursuing a number of capital formation opportunities. This includes sourcing low-cost credit facilities, short-term loans, and traditional equity financing. The company is also evaluating the creation of a Strategic Bitcoin Treasury program to leverage future crypto acquisitions. Through these efforts, management has identified significant plausible capital resources to support its operations and fuel future growth. Bullet Blockchain is actively building a comprehensive, secure, and user-centric ecosystem through strategic partnerships. These alliances are focused primarily on two endeavors. One is focused on enhancing the customer experience by providing advanced security solutions for digital assets and crypto wallets. The other is facilitating new use cases such as efficient international remittances and developing new technology offerings that create greater visibility and secondary revenue streams. These initiatives position the company not just as a Bitcoin ATM operator, but as a holistic provider of modern crypto-financial services, ultimately transforming the crypto kiosk from a single-purpose device into a multi-faceted hub for digital finance and commerce. Building on a Vision of Proven Execution These initiatives collectively form the framework for Bullet Blockchain's strategy to move from intent to execution. With its foundational patents [Nos. US9135787B1 & US10332205B1 ], and a clear roadmap for growth, management is confident in the Company's ability to generate significant value for stakeholders while establishing Bullet Blockchain as a trusted and innovative, global leader, in the crypto ATM market—intricately intertwined in the overall fabric of digital financial services and fintech. Mr. Rubin, concluded, 'Our comprehensive strategy is built on a foundation of tangible pillars, not just ambition. We are committed to moving from strategic intent to proven execution, and we are confident that our roadmap will not only generate significant long-term value, but will also establish Bullet Blockchain as the definitive leader in both the traditional capital markets and digital financial services space.' Bullet Blockchain's Intellectual Property As previously announced, Bullet Blockchain acquired First Bitcoin Capital LLC, gaining ownership of an intellectual property portfolio that includes two Bitcoin ATM patents. By virtue of its subsidiary, First Bitcoin Capital LLC, Bullet Blockchain holds the exclusive rights to U.S. Patent Nos. US9135787B1 ('Bitcoin kiosk/ATM device and system integrating enrollment protocol and method of using the same') and US10332205B1 ('Bitcoin kiosk/ATM device and system and method of using the same'). These patents remain critical technologies for the operation and security of Bitcoin ATMs and their networks. Bullet Blockchain continues to advance its licensing initiatives, offering operators and manufacturers a variety of partnership models including transaction-based fees and revenue-sharing opportunities centered around its intellectual property. About Bullet Blockchain Headquartered in Las Vegas, Nevada, Bullet Blockchain Inc. – common stock is publicly traded on the OTC Markets under the symbol (BULT) – is a diversified software development and BaaS company, specializing in blockchain technologies and Web 3.0, and though its wholly owned subsidiary, First Bitcoin Capital LLC, the owner and licensor of two Bitcoin ATM patents. Bullet Blockchain's Bitcoin ATMs are operated by licensed third-party operators within the jurisdictions in which they reside. Bullet Blockchain is committed to driving the innovations needed to shape the future of digital and blockchain-related platforms through digital technology and decentralized blockchain solutions. Management is dedicated to rapid growth and increasing the shareholders' value. Shareholders, potential investors, and others should note that we announce material events and material financial information to our shareholders and the public using our website and the social media addresses listed below, as well as in our OTC Markets' disclosures, press releases, public conference calls, and webcasts. We also use social media to communicate with our email subscribers and the public about Bullet Blockchain, services, and other related information. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage shareholders, the media, and others interested in Bullet Blockchain to review the information we post on Bullet Blockchain's social media channels listed below. This list may be updated from time to time. For investor and general information, please email contact@ Find investor and general information at Forward-Looking Statements: Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release, and these views could change at some point in the future. However, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intend,' 'anticipate,' 'anticipates,' 'plans," "plans," "plan," to be uncertain and forward-looking.


Globe and Mail
a few seconds ago
- Globe and Mail
Expeditors Q2 Earnings & Revenues Beat Estimates, Improve Y/Y
Expeditors International of Washington 's EXPD second-quarter 2025 earnings of $1.34 per share beat the Zacks Consensus Estimate of $1.24. The bottom line increased 8.1% year over year. Results were aided by higher freight volumes and customs fees. Total revenues of $2.65 billion beat the Zacks Consensus Estimate of $2.4 billion and increased 8.7% year over year, owing to strong growth in air tonnage and ocean volumes. Airfreight tonnage increased 7% during the quarter and ocean container volume also increased 7%. Operating income increased 11% year over year to $248 million. Total operating expenses increased 8.6% year over year to $2.4 billion. Airfreight Services revenues increased 10.6% year over year to $951.8 million in the second quarter of 2025. Ocean freight and ocean services revenues inched up 3.7% year over year to $675.8 million. Customs Brokerage and other services revenues increased 10.5% year over year to $1 billion. During the second quarter of 2025, EXPD rewarded its shareholders to the tune of $335 million, through dividends and share buybacks. EXPD exited the second quarter with cash and cash equivalents of $1.16 billion compared with $1.15 billion at the 2024 end. Expressing optimism about the surrounding scenario, Daniel R. Wall, president and chief executive officer of EXPD, said, 'Throughout the Expeditors global network, we are seeing the positive impact of our strategic initiatives to maximize operational excellence. Our focus on growth and execution puts us in a strong position to quickly adapt to this highly unpredictable environment. We are working with each of our regions and districts to increase efficiency and further optimize customer service to drive organic growth and boost profitability'. Currently, Expeditors carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Q2 Performances of Some Other Transportation Companies Delta Air Lines DAL reported second-quarter 2025 earnings (excluding $1.17 from non-recurring items) of $2.10 per share, which beat the Zacks Consensus Estimate of $2.04. Earnings decreased 11% on a year-over-year basis due to high labor costs. Revenues in the June-end quarter were $16.65 billion, beating the Zacks Consensus Estimate of $16.2 billion and decreasing marginally on a year-over-year basis. Adjusted operating revenues (excluding third-party refinery sales) increased 1% year over year to $15.5 billion. J.B. Hunt Transport Services JBHT reported second-quarter 2025 earnings of $1.31 per share, which missed the Zacks Consensus Estimate of $1.34 and declined 0.8% year over year. Total operating revenues of $2.93 billion missed the Zacks Consensus Estimate of $2.94 billion and were flat year over year. JBHT's second-quarter revenue performance witnessed a 6% increase in Intermodal (JBI) loads, a 13% increase in Truckload (JBT) loads, a 3% increase in Dedicated Contract Services (DCS) productivity and a 6% increase in Integrated Capacity Solutions (ICS) revenue per load. These items were offset by Final Mile Services revenue declining 10%, lower revenue per load in both JBI and JBT, a 9% decrease in ICS load volume and a 3% decline in average trucks in DCS. Total operating revenues, excluding fuel surcharge revenues, increased 1% on a year-over-year basis. United Airlines UAL reported mixed second-quarter 2025 results wherein the company's earnings beat the Zacks Consensus Estimate, but revenues missed the same. UAL's second-quarter 2025 adjusted earnings per share of $3.87 beat the Zacks Consensus Estimate by a penny but declined 6.5% on a year-over-year basis. The reported figure lies within the guided range of $3.25-$4.25 per share. Operating revenues of $15.2 billion missed the Zacks Consensus Estimate of $15.4 billion but increased 1.7% year over year. Passenger revenues (which accounted for 90.8% of the top line) increased 1.1% year over year to $13.8 billion. UAL flights transported 46,186 passengers in the second quarter, up 4.1% year over year. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report United Airlines Holdings Inc (UAL): Free Stock Analysis Report J.B. Hunt Transport Services, Inc. (JBHT): Free Stock Analysis Report Expeditors International of Washington, Inc. (EXPD): Free Stock Analysis Report